Pfizer Inc. Company Summary |
|
Pfizer Inc.(NASDAQ: PFE). The Group's principal activities are to discover, develop, manufacture and market prescription medicines for humans and animals as well as many of the world's best-known consumer products. The Group operates in two business segments pharmaceuticals and consumer products. Pharmaceuticals segment includes prescription pharmaceuticals for treating cardiovascular diseases, infectious diseases, central nervous system disorders, diabetes, erectile dysfunction, allergies, arthritis and other disorders. The major revenue generating pharmaceutical products are Lipitor, Norvasc, Cardura, Accupril, Zithromax, Viracept, Zoloft, Neurontin, Viagra and Zyrtec. Consumer products segment includes consumer health care products, confectionery products, shaving products and tetra fish products. Pharmaceutical products accounted for 84% of 2001 revenues and consumer products, 16%.
|
|
 |
Asian Activities Report for December 7, 2011: Great Wall Motors (HKG:2333) Receives EU Whole Vehicle Type Approval for Voleex C30 and Voleex C20R
DEC 7, 2011 11:27 - Article Views: 1,078
Asian Activities Report for December 7, 2011 includes: Great Wall Motors (HKG:2333) has received EU Whole Vehicle Type Approval for its Voleex C30 and Voleex C20R; Chevalier International Holdings Limited (HKG:0025) has entered into a letter of intent in relation to possible acquisitions of certain hot spring hotels in Japan; Daiichi Sankyo Co., Ltd (TYO:4568) advises that its subsidiary Ranbaxy Laboratories Ltd. (BOM:500359), India's largest pharmaceutical company, has received final approval from the U.S. Food and Drug Administration to manufacture and market Atorvastatin, a cholesterol-reducing medicine, in the US market. |
 |
 |
Benitec Limited (ASX:BLT) Receives Dividend from Licensee
DEC 23, 2010 16:18 - Article Views: 1,773
Benitec Limited (ASX:BLT) (PINK:BNIKF) is pleased to advise that it will receive a dividend of US$161,674 from its licensee, the California-based biotechnology company, Tacere Therapeutics, Inc. |
|
 |
Australian Market Report of December 20, 2010: IMX Resources (ASX:IXR) Sailed First Shipment of Iron-Copper Ore to China
DEC 20, 2010 13:30 - Article Views: 2,334
Australian Market Report of December 20, 2010 includes: IMX Resources Limited (ASX:IXR) has sailed its first shipment of iron-copper ore to China; Phylogica Limited (ASX:PYC) signed collaboration and licensing deal with Pfizer (NYSE:PFE); Copper Strike Limited (ASX:CSE) received strong copper/silver/cobalt results at Walford Creek in Northwest Queensland; South American Ferro Metals Limited (ASX:SFZ) iron ore production in Brazil exceeds 400,000 tonnes. |
|
|
Benitec Limited (ASX:BLT) Granted Further Hepatitis C RNAi Patent In US
SEP 29, 2010 11:02 - Article Views: 1,316
Benitec Limited (ASX:BLT) (PINK:BNIKF), a leading Australian based company specialising in RNA interference (RNAi) technology, is pleased to announce that the US patent application for "RNAi Expression Constructs" has been successfully granted by the United States Patent and Trademark Office (USPTO) as US Patent No. 7,803,611. |
|
|
Benitec Limited (ASX:BLT) Half Yearly Accounts
FEB 26, 2010 15:19 - Article Views: 3,398
Benitec Limited (ASX:BLT) (PINK:BNIKF) is one of the pioneers of RNA interference (RNAi) technology, which can be used to precisely destroy RNA viruses and silence the expression of defective genes. Benitec's core patents and licenses provide key technologies to trigger RNAi in human cells and in live animals. Benitec holds exclusive worldwide rights for the development and commercialisation of all therapeutic human applications. |
|
 |
ABN Newswire Stocks to Watch: February 8, 2010
FEB 8, 2010 11:30 - Article Views: 4,879
ABN Newswire stocks to watch today include: Emergent Resources Limited (ASX:EMG), Benitec Limited (ASX:BLT)(PINK:BNIKF), Legend Mining Limited (ASX:LEG) (PINK:LGDMF) and Drillsearch Energy Limited (ASX:DLS) (PINK:DRLLF). |
|
 |
Benitec Limited (ASX:BLT) Licensee Achieves Significant Milestone With Pfizer (NYSE:PFE)
FEB 5, 2010 10:38 - Article Views: 3,949
Benitec Limited (ASX:BLT)(PINK:BNIKF) licensee company Tacere Therapeutics, Inc. announced today that Pfizer (NYSE:PFE) has exercised the option, granted in a collaboration and license agreement previously announced in January 2008, to further develop and commercialise Tacere's Hepatitis C Virus (HCV) compounds. |
|
